Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims

1. (original) A pharmaceutical composition comprising activated protein C and a chelating agent.

2. (original) The composition of claim 1 wherein the pharmaceutical composition is a lyophilized formulation

3. (original) The composition of claim 2 further comprising a bulking agent.

4. (amended) The composition of claim 3 wherein the bulking agent is selected from the group consisting of mannitol, trehalose, raffinose, ~~and~~ sucrose, and mixtures thereof.

5. (amended) The composition of claim 4 further comprising a buffer selected from the group consisting of Tris-acetate, sodium citrate, ~~and~~ sodium phosphate, and ~~or~~ combinations thereof.

6. (original) The composition of claim 5 further comprising a buffer such that upon reconstitution the formulation has a pH of about 5.5 to about 6.5.

7. (original) The composition of claim 6 further comprising a salt.

8. (amended) The composition of claim 7 wherein the salt is selected from the group consisting of potassium chloride and ~~or~~ sodium chloride.

9. (original) A pharmaceutical composition comprising activated protein C, a diluent, and a chelating agent.

10. (original) The composition of claim 9 wherein the pharmaceutical composition is a lyophilized formulation.

11. (original) The composition of claim 9 wherein the diluent is a reconstitution diluent.

12. (original) The composition of claim 9 wherein the diluent is an intravenous infusion solution.

13. (original) The composition of claim 9 wherein the chelating agent is present in the diluent.

14. (original) The composition of claim 10 further comprising a bulking agent.

15. (amended) The composition of claim 14 ~~11~~ wherein the bulking agent is selected from the group consisting of mannitol, trehalose, raffinose, ~~and~~ sucrose, and mixtures thereof.

16. (amended) The composition of claim 15 ~~12~~ further comprising a buffer selected from the group consisting of Tris-acetate, sodium citrate, ~~and~~ sodium phosphate, and ~~or~~ combinations thereof.

17. (amended) The composition of claim 16 ~~13~~ further comprising a buffer such that upon reconstitution the formulation has a pH of about 5.5 to about 6.5.

18. (amended) The composition of claim 17 ~~14~~ further comprising a salt.

19. (amended) The composition of claim 18 ~~15~~ wherein the salt is selected from the group consisting of potassium chloride and ~~or~~ sodium chloride.

20. (original) A process for preparing a lyophilized formulation of aPC, which comprises freeze drying a pharmaceutical formulation containing activated protein C and a chelating agent.

21. (original) A process for preparing a lyophilized formulation of aPC, which comprises freeze drying a pharmaceutical formulation containing activated protein C, a bulking agent, and a chelating agent.

22. (original) A process of preparing a pharmaceutical solution of aPC, which comprises reconstituting a lyophilized formulation containing activated protein C with a diluent containing a chelating agent.

23. (original) A process of preparing a pharmaceutical solution of aPC, which comprises reconstituting a lyophilized formulation containing activated protein C and a bulking agent with a diluent containing a chelating agent.

24. (original) A method of treating a patient in need thereof which comprises administering to the patient the pharmaceutical composition of any one of claims 1 through 19.

25. (canceled)